Literature DB >> 31617176

oHSV Genome Editing by Means of galK Recombineering.

Laura Menotti1, Valerio Leoni2, Valentina Gatta2, Biljana Petrovic3, Andrea Vannini2, Simona Pepe2, Tatiana Gianni2, Gabriella Campadelli-Fiume4.   

Abstract

Since the cloning of the herpes simplex virus (HSV) genome as BAC (bacterial artificial chromosome), the genetic engineering of the viral genome has become readily feasible. The advantage is that the modification of the animal virus genome is carried out in bacteria, with no replication or production of viral progeny, and is separated from the reconstitution or regeneration of the recombinant virus in mammalian cells. This allows an easy engineering of essential genes, as well. Many technologies have been developed for herpesvirus BAC engineering. In our hands the most powerful is galK recombineering that exploits a single marker (galK) for positive and negative selection and PCR amplicons for seamless modification in the desired genome locus. Here we describe the engineering of the HSV recombinant BAC 115 by the insertion of a heterologous cassette for the expression of murine interleukin 12 (mIL12) in the intergenic sequence between US1 and US2 ORFs.

Entities:  

Keywords:  Herpes simplex virus; Interleukin 12; Oncolytic virotherapy; Transgene expression; Virus arming; Virus engineering; galK recombineering

Year:  2020        PMID: 31617176     DOI: 10.1007/978-1-4939-9814-2_7

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  3 in total

Review 1.  Herpes Simplex Virus Oncolytic Immunovirotherapy: The Blossoming Branch of Multimodal Therapy.

Authors:  Laura Menotti; Elisa Avitabile
Journal:  Int J Mol Sci       Date:  2020-11-05       Impact factor: 5.923

2.  Towards a Precision Medicine Approach and In Situ Vaccination against Prostate Cancer by PSMA-Retargeted oHSV.

Authors:  Andrea Vannini; Federico Parenti; Daniela Bressanin; Catia Barboni; Anna Zaghini; Gabriella Campadelli-Fiume; Tatiana Gianni
Journal:  Viruses       Date:  2021-10-16       Impact factor: 5.048

3.  Specificity, Safety, Efficacy of EGFRvIII-Retargeted Oncolytic HSV for Xenotransplanted Human Glioblastoma.

Authors:  Irene Appolloni; Francesco Alessandrini; Laura Menotti; Elisa Avitabile; Daniela Marubbi; Noemi Piga; Davide Ceresa; Francesca Piaggio; Gabriella Campadelli-Fiume; Paolo Malatesta
Journal:  Viruses       Date:  2021-08-24       Impact factor: 5.048

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.